Page 11 - PhD GT

Table 8.10
Table 8.11 Table 8.12 Table 8.13 Table 8.14
Table 8.15
Table 8.16 Table 9.1
Table 9.2 Table 9.3 Table 9.4 Table 9.5
Table 9.6
Table 9.7
Table 9.8
Numbers and percentages of participants abstinent, using intermittently or using daily at intake (t1) and at twelve month follow-up (t3) p172
t1 data by substance p174
Changes detected between t1 and t2, t2 and t3, t1 and t3 in Sample 6c p176
Changes detected between t1 and t2, t2 and t3, t1 and t3 in Sample 6c p177
Correlations between the number of days per week using and the amount used on the heaviest day (qf) by substance p178
Correlations among dependence scores, amount used on heaviest day of the past week and number of days of the past week using at each of the three data collection points: Spearman’s rho correlation coefficients p178
Correlations between duration of abstinence and mean total dependence scores at each of the data collection points: Spearman’s rho correlation coefficients p179
Correlations between total dependence scores at t1 (LDQ t1) and t2 (LDQ t2), t2 and t3 (LDQ t3) and t1 and t3: Spearman’s rho correlation coefficients and levels of significance p183
Change in dependence between intake and three months, three months and twelve months and intake and twelve months: mean, median and mode change scores p185
Percentages of the cohort who had change and no change in mean dependence scores between t1 and t2, t2 and t3, and t1 and t3 p185
Changes in mean dependence scores for numbers of individuals between the first and second and the second and third data collection points p186
Total dependence scores at intake (t1) and three months (t2), and the difference between these scores for those in Sample 6c who achieved a reliable change in their dependence score at t2 p188
Total dependence and change scores for those in Sample 6c (n=101) who met the two criteria for clinically significant change over the first three month follow-up period p189
Percentage of participants in each drug group who had statistically reliable change and clinically significant change by drug group in the first three month follow-up period p190
Total dependence and change scores for those in Sample 6c who met the two criteria for clinically significant change over the follow-up period between three months and twelve months p190
xiii